Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells.

Gui J, Katlinski KV, Koumenis C, Diehl JA, Fuchs SY.

Mol Cancer Res. 2019 Mar 22. doi: 10.1158/1541-7786.MCR-19-0002. [Epub ahead of print]

PMID:
30902831
2.

An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY.

Cancer Cell. 2019 Jan 14;35(1):33-45.e6. doi: 10.1016/j.ccell.2018.12.001.

PMID:
30645975
3.

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY.

Cancer Cell. 2017 Feb 13;31(2):194-207. doi: 10.1016/j.ccell.2017.01.004.

4.

A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.

Zhang KJ, Yin XF, Yang YQ, Li HL, Xu YN, Chen LY, Liu XJ, Yuan SJ, Fang XL, Xiao J, Wu S, Xu HN, Chu L, Katlinski KV, Katlinskaya YV, Guo RB, Wei GW, Wang DC, Liu XY, Fuchs SY.

Clin Cancer Res. 2017 Apr 15;23(8):2038-2049. doi: 10.1158/1078-0432.CCR-16-1386. Epub 2016 Sep 28.

5.

Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.

Gui J, Gober M, Yang X, Katlinski KV, Marshall CM, Sharma M, Werth VP, Baker DP, Rui H, Seykora JT, Fuchs SY.

J Invest Dermatol. 2016 Oct;136(10):1990-2002. doi: 10.1016/j.jid.2016.06.608. Epub 2016 Jun 29.

6.

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA, Fuchs SY.

Cell Rep. 2016 Apr 5;15(1):171-180. doi: 10.1016/j.celrep.2016.03.006. Epub 2016 Mar 24.

7.

Type I Interferons Control Proliferation and Function of the Intestinal Epithelium.

Katlinskaya YV, Katlinski KV, Lasri A, Li N, Beiting DP, Durham AC, Yang T, Pikarsky E, Lengner CJ, Johnson FB, Ben-Neriah Y, Fuchs SY.

Mol Cell Biol. 2016 Jan 25;36(7):1124-35. doi: 10.1128/MCB.00988-15.

8.

Type I interferons mediate pancreatic toxicities of PERK inhibition.

Yu Q, Zhao B, Gui J, Katlinski KV, Brice A, Gao Y, Li C, Kushner JA, Koumenis C, Diehl JA, Fuchs SY.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15420-5. doi: 10.1073/pnas.1516362112. Epub 2015 Dec 1.

9.

DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function.

Yu Q, Katlinskaya YV, Carbone CJ, Zhao B, Katlinski KV, Zheng H, Guha M, Li N, Chen Q, Yang T, Lengner CJ, Greenberg RA, Johnson FB, Fuchs SY.

Cell Rep. 2015 May 5;11(5):785-797. doi: 10.1016/j.celrep.2015.03.069. Epub 2015 Apr 23.

10.

Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury.

Bhattacharya S, Katlinski KV, Reichert M, Takano S, Brice A, Zhao B, Yu Q, Zheng H, Carbone CJ, Katlinskaya YV, Leu NA, McCorkell KA, Srinivasan S, Girondo M, Rui H, May MJ, Avadhani NG, Rustgi AK, Fuchs SY.

EMBO Mol Med. 2014 Mar;6(3):384-97. doi: 10.1002/emmm.201303236. Epub 2014 Jan 30.

Supplemental Content

Loading ...
Support Center